AnteoTech Completes Initial Stage of Collaborative Immunoassay Product Development Program; Shares Jump 18%

MT Newswires Live

Jul 01

AnteoTech (ASX:ADO) completed the initial stage of a collaborative immunoassay product development work program, according to a Wednesday Australian bourse filing.

The program is focused on the development of AnteoBind NXT activated magnetic particles for chemiluminescent immunoassays (CLIA).

The initial stage involved performance testing of the magnetic particles, supplied by an unnamed global life sciences company, for their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms.

The next stage of work has been agreed and is about to begin, the company said.

AnteoTech's shares jumped nearly 18% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2648200594"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2648200594\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2648200594?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 12:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648200594","market":"us","top_or_hot":-1,"title":"AnteoTech Completes Initial Stage of Collaborative Immunoassay Product Development Program; Shares Jump 18%","media":"MT Newswires Live","content":"<html><body><p> AnteoTech (ASX:ADO) completed the initial stage of a collaborative immunoassay product development work program, according to a Wednesday Australian bourse filing.</p><p>The program is focused on the development of AnteoBind NXT activated magnetic particles for chemiluminescent immunoassays (CLIA).</p><p>The initial stage involved performance testing of the magnetic particles, supplied by an unnamed global life sciences company, for their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms.</p><p>The next stage of work has been agreed and is about to begin, the company said.</p><p>AnteoTech's shares jumped nearly 18% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnteoTech Completes Initial Stage of Collaborative Immunoassay Product Development Program; Shares Jump 18%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnteoTech Completes Initial Stage of Collaborative Immunoassay Product Development Program; Shares Jump 18%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-01 12:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AnteoTech (ASX:ADO) completed the initial stage of a collaborative immunoassay product development work program, according to a Wednesday Australian bourse filing.</p><p>The program is focused on the development of AnteoBind NXT activated magnetic particles for chemiluminescent immunoassays (CLIA).</p><p>The initial stage involved performance testing of the magnetic particles, supplied by an unnamed global life sciences company, for their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms.</p><p>The next stage of work has been agreed and is about to begin, the company said.</p><p>AnteoTech's shares jumped nearly 18% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7048","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648200594","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648200594","pubTimestamp":1782880777,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AnteoTech  completed the initial stage of a collaborative immunoassay product development work program, according to a Wednesday Australian bourse filing.The program is focused on the development of AnteoBind NXT activated magnetic particles for chemiluminescent immunoassays .The initial stage involved performance testing of the magnetic particles, supplied by an unnamed global life sciences company, for their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms.The next stage of work has been agreed and is about to begin, the company said.AnteoTech's shares jumped nearly 18% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7048":"生命科学工具和服务","BK7508":"医药生物股","BK7036":"特种化学制品","ADO.AU":"AnteoTech Ltd","BK7501":"新冠治疗股","CLIA":"VERIDIEN CLIMATE ACTION ETF"},"translate_title":"AnteoTech完成合作免疫测定产品开发计划的初始阶段；股价上涨18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLIA":1,"ADO.AU":1},"content_text":"AnteoTech (ASX:ADO) completed the initial stage of a collaborative immunoassay product development work program, according to a Wednesday Australian bourse filing.The program is focused on the development of AnteoBind NXT activated magnetic particles for chemiluminescent immunoassays (CLIA).The initial stage involved performance testing of the magnetic particles, supplied by an unnamed global life sciences company, for their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms.The next stage of work has been agreed and is about to begin, the company said.AnteoTech's shares jumped nearly 18% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}